You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 637 Immune-related adverse events (irAEs) may indicate a favorable prognosis in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI)

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Immunotherapy toxicities
637 Immune-related adverse events (irAEs) may indicate a favorable prognosis in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Martini D, Evans S, Goyal S, et al
637 Immune-related adverse events (irAEs) may indicate a favorable prognosis in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI)
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0637